Salarius Pharmaceuticals Completes Merger With Decoy Therapeutics and Raises $8 Million

Reuters11-20

Salarius Pharmaceuticals Completes Merger With Decoy <a href="https://laohu8.com/S/LENZ">Therapeutics</a> and Raises $8 Million

Salarius Pharmaceuticals has completed its previously announced merger with Decoy Therapeutics, combining the two companies to focus on advancing Decoy's pipeline of peptide conjugate therapeutics. Following the merger and a recent underwritten public offering that raised $8 million in gross proceeds, the combined company has pro forma cash of approximately $14 million and approximately 5.9 million shares of common stock outstanding. Salarius stated that its shares continue to trade on the Nasdaq Stock Market under the ticker symbol "SLRX." The company is prioritizing the development of Decoy's lead asset, a pan-coronavirus antiviral, with plans to submit an IND application to the FDA within the next 12 months, and is also progressing other programs targeting flu, COVID-19, RSV, and gastrointestinal cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief on November 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584213978?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 03:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584213978","market":"nz","top_or_hot":-1,"title":"Salarius Pharmaceuticals Completes Merger With Decoy Therapeutics and Raises $8 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Salarius Pharmaceuticals Completes Merger With Decoy <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and Raises $8 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Salarius Pharmaceuticals has completed its previously announced merger with Decoy Therapeutics, combining the two companies to focus on advancing Decoy's pipeline of peptide conjugate therapeutics. Following the merger and a recent underwritten public offering that raised $8 million in gross proceeds, the combined company has pro forma cash of approximately $14 million and approximately 5.9 million shares of common stock outstanding. Salarius stated that its shares continue to trade on the Nasdaq Stock Market under the ticker symbol \"SLRX.\" The company is prioritizing the development of Decoy's lead asset, a pan-coronavirus antiviral, with plans to submit an IND application to the FDA within the next 12 months, and is also progressing other programs targeting flu, COVID-19, RSV, and gastrointestinal cancers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SLRX\">Salarius Pharmaceuticals Inc</a>. published the original content used to generate this news brief on November 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Salarius Pharmaceuticals Completes Merger With Decoy Therapeutics and Raises $8 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSalarius Pharmaceuticals Completes Merger With Decoy Therapeutics and Raises $8 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 03:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Salarius Pharmaceuticals Completes Merger With Decoy <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and Raises $8 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Salarius Pharmaceuticals has completed its previously announced merger with Decoy Therapeutics, combining the two companies to focus on advancing Decoy's pipeline of peptide conjugate therapeutics. Following the merger and a recent underwritten public offering that raised $8 million in gross proceeds, the combined company has pro forma cash of approximately $14 million and approximately 5.9 million shares of common stock outstanding. Salarius stated that its shares continue to trade on the Nasdaq Stock Market under the ticker symbol \"SLRX.\" The company is prioritizing the development of Decoy's lead asset, a pan-coronavirus antiviral, with plans to submit an IND application to the FDA within the next 12 months, and is also progressing other programs targeting flu, COVID-19, RSV, and gastrointestinal cancers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SLRX\">Salarius Pharmaceuticals Inc</a>. published the original content used to generate this news brief on November 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLRX","symbol_name":"Salarius Pharmaceuticals Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL2wNMCY:1","article_id":"2584213978","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584213978","pubTimestamp":1763581738,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Salarius Pharmaceuticals has completed its previously announced merger with Decoy Therapeutics, combining the two companies to focus on advancing Decoy's pipeline of peptide conjugate therapeutics. Following the merger and a recent underwritten public offering that raised $8 million in gross proceeds, the combined company has pro forma cash of approximately $14 million and approximately 5.9 million shares of common stock outstanding. Salarius stated that its shares continue to trade on the Nasdaq Stock Market under the ticker symbol \"SLRX.\" The company is prioritizing the development of Decoy's lead asset, a pan-coronavirus antiviral, with plans to submit an IND application to the FDA within the next 12 months, and is also progressing other programs targeting flu, COVID-19, RSV, and gastrointestinal cancers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLRX":"Salarius Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"Salarius Pharmaceuticals完成与Decoy Therapeutics的合并并筹集800万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLRX":0.9},"content_text":"Salarius Pharmaceuticals Completes Merger With Decoy Therapeutics and Raises $8 Million\n    \n\n        Salarius Pharmaceuticals has completed its previously announced merger with Decoy Therapeutics, combining the two companies to focus on advancing Decoy's pipeline of peptide conjugate therapeutics. Following the merger and a recent underwritten public offering that raised $8 million in gross proceeds, the combined company has pro forma cash of approximately $14 million and approximately 5.9 million shares of common stock outstanding. Salarius stated that its shares continue to trade on the Nasdaq Stock Market under the ticker symbol \"SLRX.\" The company is prioritizing the development of Decoy's lead asset, a pan-coronavirus antiviral, with plans to submit an IND application to the FDA within the next 12 months, and is also progressing other programs targeting flu, COVID-19, RSV, and gastrointestinal cancers.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief on November 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584213978","isCrawlerRequest":true}